Researcher
Benedicte De Winter
- Research Expertise:- Visceral pain - Inflammation - ileus - irritable bowel syndrome - IBS - inflammatory bowel disease - IBD - sepsis - experimental and clinical translational research - medisch vaardighedenonderwijs
- Keywords:VISCERAL PAIN, SEPSIS, IRRITABLE BOWEL SYNDROME, INFLAMMATION, INFLAMMATORY BOWEL DISEASE, Medicine
- Disciplines:Gastro-enterology, Inflammation, Pathophysiology
- Research techniques:- in vivo animal models of IBS, IBD and sepsis - visceromotor response and afferent neuronal activity - motility and sensitivity assays - inflammation measurements - Elisa, flowcytometry - vaardigheden, portfolio, stationsproeven
- Users of research expertise:- research labs - pharmaceutical industry - (bio-, para-) medical schools
Affiliations
- Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Responsible
From1 Oct 2013 → Today - Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Member
From1 Oct 2003 → 30 Sep 2013 - Primary and interdisciplinary care Antwerp (ELIZA) (Research group)
Member
From1 Oct 2003 → 30 Sep 2008
Projects
1 - 10 of 32
- Automation of a mucin mRNA isoform-based biomarker platform to monitor patients with inflammatory bowel diseases.From1 Apr 2024 → TodayFunding: IOF - technology validation in lab
- Crosstalk between MUC13 signalling and the mucosal microbiota in gastric cancer development.From1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- REspiratory Virus Repository ANTwerp (ReViRAnt).From1 Jan 2023 → TodayFunding: Flemish Resilience. Government of Flanders Recovery Plan - strengthening R&D
- Turning the understanding of inflammation-related pathology into new biomarkers and treatments using next-generation technologies and high-throughput data mining.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases.From1 Sep 2022 → 31 Aug 2023Funding: IOF - technology validation in lab
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Assessing health effects of air pollution by non-invasive exhaled breath analysis (ALERT).From1 Jun 2021 → 31 May 2023Funding: Provinces
- Mucin isoform-microbiome crosstalk shaping the course of COVID-19: a help in patient stratification?From1 Nov 2020 → 31 Oct 2021Funding: FWO Special Call for Covid-19 research projects, BOF - projects
- Study of the mechanisms involved in MUC1/MUC13-induced intestinal barrier disruption during inflammatory bowel diseases: a translational approach.From1 Nov 2020 → TodayFunding: FWO junior postdoctoral fellowship
- Functional characterization of human mast cells and basophils in the pathophysiology of diarrhea-predominant irritable bowel syndrome.From1 Oct 2020 → 30 Sep 2022Funding: FWO fellowships
Publications
41 - 50 of 165
- A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity(2021)
Authors: Annemieke Smet, Tom Breugelmans, Johan Michiels, Kevin Lamote, Wout Arras, Joris De Man, Leo Heyndrickx, Anne Hauner, Manon Huizing, Surbhi Malhotra, et al.
- Functional respiratory imaging provides novel insights into the long-term respiratory sequelae of bronchopulmonary dysplasia(2021)
Authors: Kristien Vanhaverbeke, Maria Slaats, Mohammed Al-Nejar, Niek Everaars, Annemiek Snoeckx, Maarten Spinhoven, Eline Lauwers, Annelies Van Eyck, Benedicte De Winter, Kim Van Hoorenbeeck, et al.
- Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy(2021)
Authors: Margot Geens, Sofie Stappers, Heleen Konings, Benedicte De Winter, Pol Specenier, Jan van Meerbeeck, Gert Verpooten, Steven Abrams, Marc Peeters, Paul Van de Heyning, et al.
- Local colonic administration of a serine protease inhibitor improves post-inflammatory visceral hypersensitivity in rats(2021)
Authors: Nikita Hanning, Michelle De bruyn, Hannah Ceuleers, Tim Boogaerts, Maya Berg, Annemieke Smet, Heiko De Schepper, Jurgen Joossens, Alexander van Nuijs, Joris De Man, et al.
- Intestinal barrier dysfunction in irritable bowel syndrome(2021)
Authors: Nikita Hanning, Adam L. Edwinson, Hannah Ceuleers, Stephanie A. Peters, Joris De Man, Leslie C. Hassett, Benedicte De Winter, Madhusudan Grover
- Proteolytic cleavage of bioactive peptides and protease-activated receptors in acute and post-colitis(2021)
Authors: Michelle De bruyn, Hannah Ceuleers, Nikita Hanning, Maya Berg, Joris De Man, Paco Hulpiau, Cedric Hermans, Ulf-Hakan Stenman, Hannu Koistinen, Benedicte De Winter, et al.
- The impact of obstructive sleep apnea on endothelial function during weight loss in an obese pediatric population(2021)
Authors: Sofie Jacobs, Emilie Mylemans, Marijke Ysebaert, Eline Vermeiren, Ann De Guchtenaere, Hilde Heuten, Luc Bruyndonckx, Benedicte De Winter, Kim Van Hoorenbeeck, Stijn Verhulst, et al.
Pages: 48 - 55 - Comparison of bioimpedance spectroscopy and dual energy X-ray absorptiometry for assessing body composition changes in obese children during weight loss(2021)
Authors: Eline Vermeiren, Marijke Ysebaert, Luc Bruyndonckx, Kristof Van Dessel, Maria Van Helvoirt, Ann De Guchtenaere, Benedicte De Winter, Stijn Verhulst
Pages: 73 - 84 - The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13 - Clinical- and surgery-specific risk factors for post-operative sepsis(2020)
Authors: Philip Plaeke, Joris De Man, Philippe Jorens, Benedicte De Winter, Guy Hubens
Pages: 427 - 439
Patents
1 - 9 of 9
- Method for determining the severity and prognosis of rsv infection (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Method for determining the severity and prognosis of RSV infection (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
Linked dataset
1 - 1 of 1